Association of Body Composition with Long-Term Survival in Non-metastatic Rectal Cancer Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose We evaluated the association of body composition with long-term oncologic outcomes in non-metastatic rectal cancer patients. Materials and Methods We included 1,384 patients with stage(y)0-III rectal cancer treated at Asan Medical Center between January 2005 and December 2012. Body composition at diagnosis was measured using abdomino-pelvic computed tomography (CT). Sarcopenia, visceral obesity (VO), and sarcopenic obesity (SO) were defined using CT measured parameters such as skeletal muscle index (total abdominal muscle area, TAMA), visceral fat area (VFA), and VFA/TAMA. Inflammatory status was defined as a neutrophil-lymphocyte ratio of ! 3. Obesity was categorized by body mass index (! 25 kg/m2). Results Among the 1,384 patients, 944 (68.2%) had sarcopenia and 307 (22.2%) had SO. The 5-year overall survival (OS) rate was significantly lower in sarcopenic patients (no sarcopenia vs. sarcopenia; 84% vs. 78%, p=0.003) but the 5-year recurrence-free survival (RFS) rate was not different (77.3% vs. 77.9% p=0.957). Patients with SO showed lower 5-year OS (79.1% vs. 75.5% p=0.02) but no difference in 5-year RFS (p=0.957). Sarcopenia, SO, VO, and obesity were not associated with RFS. However, obesity, SO, age, sex, inflammatory status, and tumor stage were confirmed as independent factors associated with OS on multivariate analysis. In subgroup analysis, association of SO with OS was more prominent in patients with (y)p stage 0-2 and no inflammatory status. Conclusion The presence of SO and a low body mass index at diagnosis are negatively associated with OS in non-metastatic rectal cancer patients.
Abstract
Purpose We evaluated the association of body composition with long-term oncologic outcomes in non-metastatic rectal cancer patients. Materials and Methods We included 1,384 patients with stage(y)0-III rectal cancer treated at Asan Medical Center between January 2005 and December 2012. Body composition at diagnosis was measured using abdomino-pelvic computed tomography (CT). Sarcopenia, visceral obesity (VO), and sarcopenic obesity (SO) were defined using CT measured parameters such as skeletal muscle index (total abdominal muscle area, TAMA), visceral fat area (VFA), and VFA/TAMA. Inflammatory status was defined as a neutrophil-lymphocyte ratio of ! 3. Obesity was categorized by body mass index (! 25 kg/m2). Results Among the 1,384 patients, 944 (68.2%) had sarcopenia and 307 (22.2%) had SO. The 5-year overall survival (OS) rate was significantly lower in sarcopenic patients (no sarcopenia vs. sarcopenia; 84% vs. 78%, p=0.003) but the 5-year recurrence-free survival (RFS) rate was not different (77.3% vs. 77.9% p=0.957). Patients with SO showed lower 5-year OS (79.1% vs. 75.5% p=0.02) but no difference in 5-year RFS (p=0.957). Sarcopenia, SO, VO, and obesity were not associated with RFS. However, obesity, SO, age, sex, inflammatory status, and tumor stage were confirmed as independent factors associated with OS on multivariate analysis. In subgroup analysis, association of SO with OS was more prominent in patients with (y)p stage 0-2 and no inflammatory status. Conclusion The presence of SO and a low body mass index at diagnosis are negatively associated with OS in non-metastatic rectal cancer patients.
참고문헌 (28)
- Miyamoto Y, "Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer", Ann Surg Oncol, 22, pp.2663~2668 (2015)
- Shachar SS, "Prognostic value of sarcopenia in adults with solid tumours : a metaanalysis and systematic review", Eur J Cancer, 57, pp.58~67 (2016)
- Haram A, "The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer : a systematic review", J Surg Oncol, 115, pp.470~479 (2017)
- Prado CM, "Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts : a population-based study", Lancet Oncol, 9, pp.629~635 (2008)
- Malietzis G, "Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer", Ann Surg, 263, pp.320~325 (2016)
- Black D, "Prognostic value of computed tomography : measured parameters of body composition in primary operable gastrointestinal cancers", Ann Surg Oncol, 24, pp.2241~2251 (2017)
- Hopkins JJ, "The impact of muscle and adipose tissue on long-term survival in patients with stage I to III colorectal cancer", Dis Colon Rectum, 62, pp.549~560 (2019)
- Lieffers JR, "Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery", Br J Cancer, 107, pp.931~936 (2012)
- Huang DD, "Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer", Colorectal Dis, 17, pp.O256~64 (2015)
- Feliciano EM, "Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer : results from the C SCANS study", JAMA Oncol, 3, pp.e172319~ (2017)
- 백광열, "Clinical Implications of Systemic Inflammatory Response Markers as Independent Prognostic Factors in Colorectal Cancer Patients", Cancer Research and Treatment, 46(1), pp.65~73 (2014), 대한암학회
- Park JH, "Colorectal cancer, systemic inflammation, and outcome : staging the tumor and staging the host", Ann Surg, 263, pp.326~336 (2016)
- Bano G, "Inflammation and sarcopenia : a systematic review and meta-analysis", Maturitas, 96, pp.10~15 (2017)
- Harimoto N, "Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma", Br J Surg, 100, pp.1523~1530 (2013)
- Choi MH, "Sarcopenia is negatively associated with long-term outcomes in locally advanced rectal cancer", J Cachexia Sarcopenia Muscle, 9, pp.53~59 (2018)
- Baracos VE, "Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy", Ann Oncol, 29, pp.ii1~ii9 (2018)
- Carneiro IP, "Clinical implications of sarcopenic obesity in cancer", Curr Oncol Rep, 18, pp.62~ (2016)
- Gruber ES, "Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma", PLoS One, 14, pp.e0215915~ (2019)
- Coussens LM, "Inflammation and cancer", Nature, 420, pp.860~867 (2002)
- Chua W, "Neutrophil", lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer, 2011, pp.104, 1288~1295
- Tilg H, "Adipocytokines : mediators linking adipose tissue, inflammation and immunity", Nat Rev Immunol, 6, pp.772~783 (2006)
- Xing SQ, "Adiponectin induces apoptosis in hepatocellular carcinoma through differential modulation of thioredoxin proteins", Biochem Pharmacol, 93, pp.221~231 (2015)
- Trayhurn P, "Secreted proteins from adipose tissue and skeletal muscle : adipokines, myokines and adipose", muscle cross-talk, 2011, pp.117, 47~56
- Pedersen BK, "Muscles, exercise and obesity : skeletal muscle as a secretory organ", Nat Rev Endocrinol, 8, pp.457~465 (2012)
- Leitch EF, "Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer", Br J Cancer, 97, pp.1266~1270 (2007)
- Liu Y, "Prognostic role of Glasgow prognostic score in patients with colorectal cancer : evidence from population studies", Sci Rep, 7, pp.6144~ (2017)
- Broughman JR, "Prevalence of sarcopenia in older patients with colorectal cancer", J Geriatr Oncol, 6, pp.442~445 (2015)
- Reisinger KW, "Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery", Ann Surg, 261, pp.345~352 (2015)